Lifeboat Foundation

Months later, the trio of scientists published a paper that found that a virus, not a novel strain of bacteria like some within the scientific community originally thought, was to blame. Over the following decades, other scientists unfurled the gnarly branches of the large influenza family tree, gathering enough information to formulate a vaccine, which (hopefully) most of us get before every flu season.

But here’s the catch: Influenza is a master shapeshifter. Every year, strains of the virus that infect humans — influenza type A and B — evolve in ways that evade vaccines and, subsequently, our immune systems. This results in uneven vaccine effectiveness from year to year and also undermines efforts to pack a flu shot with a broad, long-lasting immune punch.

But we may have an ace in the hole thanks to mRNA, the same technology used for our Covid-19 vaccines. In a study published Monday in the journal Proceedings of the National Academy of Sciences, researchers at the University of Pennsylvania, Icahn School of Medicine at Mount Sinai, and other institutions have cooked up an mRNA-based influenza vaccine that targets four viral proteins that tend to remain the same across different strains of influenza.

“We grow them in huge bioreactors in just three weeks — while regular cannabis takes 14 to 23 weeks,” Sobel said. “Our tech can also significantly increase the levels of active ingredients, as a percent of the weight, versus what is found normally in the plant.”

An Israeli company has cloned hemp cells and used a bioreactor to grow them into a substance with all the active compounds of cannabis — and 12 times the potency.

BioHarvest Sciences says the breakthrough could make the medical benefits of cannabis available in cheaper, cleaner and greener form. It has started applying for the necessary licenses to manufacture and sell its product for medical use in Israel and the United States.

Continue reading “Cloned cannabis cells with 12 times more potency are grown in Israeli bioreactor” »

CNN

—

A single dose of a synthetic version of the mind-altering component of magic mushrooms, psilocybin, improved depression in people with a treatment-resistant form of the disease, a new study found.

Continue reading “Severe depression eased by single dose of synthetic ‘magic mushroom’” »

New images from scientists at Cold Spring Harbor Laboratory (CSHL) reveal for the first time the three-dimensional structures of a set of molecules critical for healthy brain function.

The molecules are members of a family of proteins in the brain known as NMDA receptors, which mediate the passage of essential signals between neurons. The detailed pictures generated by the CSHL team will serve as a valuable blueprint for drug developers working on new treatments for schizophrenia, depression, and other neuropsychiatric conditions.

“This NMDA receptor is such an important drug target,” says Tsung-Han Chou, a postdoctoral researcher in CSHL Professor Hiro Furukawa’s lab. That’s because dysfunctional NMDA receptors are thought to contribute to a wide range of conditions, including not just depression and schizophrenia, but also Alzheimer’s disease, stroke, and seizures. “We hope our images, which visualize the receptor for the first time, will facilitate drug development across the field based on our structural information,” Chou says.

It’s important in sports and in interpersonal relationships—perfect timing. But how does our brain learn to estimate when events might occur and react accordingly? Scientists at MPI CBS in Leipzig together with colleagues from the Kavli Institute at the Norwegian University of Science and Technology in Trondheim were able to demonstrate in an MRI study that our brain learns best in connection with constructive feedback.

Imagine playing a game with friends, where they throw you a ball that you must catch. The first couple of throws you might miss the ball, but as you keep trying, you become better at estimating the time it takes to reach you and catch it more easily. How does your brain do this? “Fundamental to this process are your abilities to learn from past experiences and to extract time-related information from the environment,” explains Ignacio Polti, who conducted the study now published in the journal eLife together with Matthias Nau and Christian Doeller.

“Every throw of your friend will be slightly different from the previous one. Some balls arrive earlier, some arrive later. During the game, your brain learns the distribution of arrival times, and it uses this information to form expectations for future throws. By combining such prior knowledge with specific information of our friend’s current throw, we can thus improve the timing of our catch attempts.”

A recent study to be presented at the American Heart Association (AHA) Scientific Sessions 2022 revealed unexpected changes in the electrical conduction system of the first genetically-modified porcine-to-human heart xenotransplant.

Xenotransplantation is the procedure of transplantation/implantation into a human of organs from non-human animal sources. The first pig-to-human heart xenograft was transplanted in January 2022 at the University of Maryland. The recipient survived for 61 days after receiving the xenograft. Research efforts have been underway for this xenotransplantation for over three decades.

Harvesting genetically-modified porcine hearts, the genes of which have been altered for safe transplantation into humans, would become a reality if successful. However, xenotransplantation of organs into a human carries several inherent challenges. With these transplant procedures, there is always the risk of graft rejection, infection, and abnormal heart rhythms.

A team of Canadian researchers from Université de Montréal has designed and validated a new class of drug transporters made of DNA that are 20,000 times smaller than a human hair and that could improve how cancers and other diseases are treated.

Reported in a new study in Nature Communications, these molecular transporters can be chemically programmed to deliver optimal concentration of drugs, making them more efficient than current methods.

Bacterial biofilm formation is a huge problem in industry and medicine. Therefore, the discovery of anti-biofilm agents may hold great promise. Biofilm formation is usually a consequence of bacterial cell–cell communication, a process called quorum sensing (QS). CeO2 nanocrystals (NCs) have been established as haloperoxidase (HPO) mimics and ecologically beneficial biofilm inhibitors. They were suggested to interfere with QS, a mechanism termed quorum quenching (QQ), but their molecular mechanism remained elusive. We show that CeO2 NCs are effective QQ agents, inactivating QS signals by bromination. Catalytic bromination of 3-oxo-C12-AHL a QS signaling compound used by Pseudomonas aeruginosa, was detected in the presence of CeO2 NCs, bromide ions, and hydrogen peroxide. Brominated acyl-homoserine lactones (AHLs) no longer act as QS signals but were not detected in the bacterial cultures.